Korean medical aesthetics and device companies are accelerating their global footprint through high-profile clinical trials, expanded China distribution, and growing US market presence. Key developments include Nextbiomedical's multicenter US trials at top hospitals, Viol's new supply deal for Sylfirm X in China, and Classys surpassing 300 RF device installations in North America. These moves signal strong momentum for overseas buyers and distributors seeking proven, regulated aesthetic technologies.
Nextbiomedical: Global Clinical Trials at Top-Ranked Hospitals
Nextbiomedical announced that its ongoing clinical trials are being conducted at multiple hospitals ranked in Newsweek's 'World's Best Hospitals 2026'. Of the 22 institutions involved (4 in Korea, 18 overseas), 12 are in the top 100. The company's flagship hemostatic powder, Nexpowder, is undergoing a first US multicenter study at Cleveland Clinic (ranked 3rd) and Brigham and Women's Hospital (18th). Nexpowder already holds approvals from Korea MFDS, US FDA, EU CE-MDR, and Japan PMDA. The post-market trial aims to strengthen clinical evidence. Another product, Nexsphere-F embolic microspheres, will be studied at Charité Hospital in Berlin (ranked 8th) in a registry trial involving about 500 patients. "Conducting clinical trials at world-class institutions with top medical staff and infrastructure is highly meaningful for credibility and competitiveness," a Nextbiomedical official said. "We will continue expanding collaboration with global hospitals to accumulate reliable clinical data."
Viol Medical: Additional Sylfirm X Supply Deal with China Partner
Viol Medical signed an additional supply agreement for Sylfirm X with its Chinese partner Sihuan Pharmaceutical at a strategic ceremony in Beijing on May 28. Sihuan has been distributing Sylfirm X in China since 2022. The new deal covers expanded marketing and medical academic support. Sylfirm X is a microneedle RF device used for scars, pores, pigmentation, and vascular concerns. Viol reported that 2025 China sales of Sylfirm X grew 139% year-on-year, driven by rising local demand and active marketing. "China is a key growth market in Asian medical aesthetics," a Viol official said. "We will strengthen academic activities and marketing with Sihuan to accelerate business growth through expanded supply."
Classys: US Market Surge and Jefferies Conference Spotlight
Classys announced it surpassed 300 cumulative installations of its monopolar RF (MRF) devices in North America last year. After launching its microneedle RF (MNRF) device this year, combined MRF and MNRF sales exceeded 100 units in Q1 alone. The company expects HIFU device approval next year, projecting North America to contribute 15% of total revenue by 2030.
Classys presented at the Jefferies Healthcare Conference in the US, a major European healthcare event with over 500 companies and 3,000 investors. The company highlighted its differentiated competitive edge in K-beauty medical devices, noting that its combination treatment protocols have boosted patient revisit rates. Global investors focused on Classys' high profitability and consumables-driven business model, as well as its country-specific product portfolio expansion strategy.
Sourcing Context: China Medical & Rehab Fairs in Suzhou
MEDICAL FAIR CHINA 2026 and REHACARE CHINA 2026 will be held concurrently in Suzhou from August 20-22. Suzhou Industrial Park hosts over 1,400 biotech companies. MFC 2026 expects 350 exhibitors and 15,000 visitors across 18,000 sqm, covering medical consumables, AI digital health, surgical robots, and IVD. REHACARE CHINA 2026 will feature 200 exhibitors including Sonova, Intco, and RoboCT. Last year's events saw 16,317 professional visitors, a 44% increase year-on-year. A Korean pavilion will be operated by the Disability Enterprise Support Center. Group buyers of 5+ people can receive travel subsidies.
What Buyers Should Watch
- Nextbiomedical's Nexpowder and Nexsphere-F are gaining clinical validation at top global hospitals, enhancing their appeal for distributors in regulated markets. - Viol's Sylfirm X continues strong China growth; additional supply deals signal sustained demand and partnership stability. - Classys' North American expansion, with over 300 RF units installed and new MNRF device, offers opportunities for distributors seeking high-margin consumables-based business models. - The Suzhou trade fairs provide a direct platform for sourcing Chinese medical devices, rehab equipment, and digital health solutions.
Source: Read the original report | Published: June 05, 2026